Unknown

Dataset Information

0

SaRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern.

ABSTRACT: Several vaccines have been widely used to counteract the global pandemic caused by SARS-CoV-2. However, due to the rapid emergence of SARS-CoV-2 variants of concern (VOCs), further development of vaccines that confer broad and longer-lasting protection against emerging VOCs are needed. Here, we report the immunological characteristics of a self-amplifying RNA (saRNA) vaccine expressing the SARS-CoV-2 Spike (S) receptor binding domain (RBD), which is membrane-anchored by fusing with an N-terminal signal sequence and a C-terminal transmembrane domain (RBD-TM). Immunization with saRNA RBD-TM delivered in lipid nanoparticles (LNP) efficiently induces T-cell and B-cell responses in non-human primates (NHPs). In addition, immunized hamsters and NHPs are protected against SARS-CoV-2 challenge. Importantly, RBD-specific antibodies against VOCs are maintained for at least 12 months in NHPs. These findings suggest that this saRNA platform expressing RBD-TM will be a useful vaccine candidate inducing durable immunity against emerging SARS-CoV-2 strains.

SUBMITTER: Komori M 

PROVIDER: S-EPMC10199074 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Several vaccines have been widely used to counteract the global pandemic caused by SARS-CoV-2. However, due to the rapid emergence of SARS-CoV-2 variants of concern (VOCs), further development of vaccines that confer broad and longer-lasting protection against emerging VOCs are needed. Here, we report the immunological characteristics of a self-amplifying RNA (saRNA) vaccine expressing the SARS-CoV-2 Spike (S) receptor binding domain (RBD), which is membrane-anchored by fusing with an N-terminal  ...[more]

Similar Datasets

Unknown The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.
| S-EPMC8426336 | biostudies-literature
Unknown RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants.
| S-EPMC8915453 | biostudies-literature
Unknown Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity.
| S-EPMC11561850 | biostudies-literature
Unknown A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern.
| S-EPMC9552159 | biostudies-literature
Unknown A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
| S-EPMC2663794 | biostudies-literature
Unknown A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens.
| S-EPMC8652677 | biostudies-literature
Unknown Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
| S-EPMC10212738 | biostudies-literature
Unknown A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.
| S-EPMC9793938 | biostudies-literature
Unknown A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
| S-EPMC10576135 | biostudies-literature
Unknown A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates.
| S-EPMC9810210 | biostudies-literature